Digital Measures: Transforming the Trajectory of Clinical Development & Patient Treatment in Neurology

Digital Measures Leading the Charge for CNS Clinical Development

As Lecanemab, Tofersen, and shortly Donanemab bring us into a new era of neuroscience breakthroughs in 2024, and SV95C is heralded as the first-ever regulatory-qualified digital biomarker, now is the time to capitalize on objective, more quantitative, and less invasive digital measures to reduce costs and improve patient experience.

With innovations in speech, cognition, sleep, motor, facial, and eye tracking identified as clinically relevant measures across a breadth of CNS indications from neurodegenerative, neuromuscular, psychiatric, and neurodevelopmental indications and epilepsies, we’re just scratching the surface of the expansive potential of digital measures in neurology.

The 3rd Digital Biomarkers & Clinical Measures for Neurology Summit welcomes 25+ key opinion leaders to the podium this August, discussing the implementation of these measures into their clinical trials, clinical development, regulatory approach, commercialization, and reimbursement strategy.

Digital Tools to Accelerate the Pipeline to Effective & Safe CNS Drugs

49140 Icon (1)

Navigating global regulatory pathways for digital biomarker qualification, precompetitive collaboration and standardization with Novartis, Merck, DEEP Measures, and Roche

49140 Icon (3)

Harness wearable devices for longitudinal monitoring of patient disease burden and improvement across epilepsies, neurodevelopmental and neuromuscular disorders with Takeda, Alexion Pharmaceuticals, Coalition of Advancing Science, and Novartis

49140 Icon (2)

Evaluating multifactorial measures of speech across ALS, Psychiatry and Parkinson’s Disease for longitudinal monitoring of disease with Boehringer, and Mitsubishi Tanabe Pharma

49140 Icon (4)

Explore real-world approaches to digital therapeutics for mental health with BMS, Boehringer Ingelheim, and Cerevel Therapeutics and cognitive impairment for earlier diagnosis and more accurate quantification of disease burden with Janssen, Regeneron, and South Shore Hospital

49140 Icon (5)

Delve into the commercialization of digital biomarkers in a real-world payer and reimbursement landscape with Pfizer, Alexion, and Harvard Medical School while prioritizing clinical relevance, usability, and patient perspectives with Biogen and Eisai

Who Will You Meet in 2024?

The 3rd Digital Biomarkers & Clinical Measures for Neurology meeting unites 80+ key pharma and biotech leaders across translational medicine, clinical development, digital health, medical affairs, and regulatory affairs.

From C-Level executives to clinical research scientists, the leading industry figures will be uniting this August to discover the latest unpublished data, hear heated panel discussions, and join deep-dive workshops you won’t find anywhere else.

49140 Audience Summary (1)
49140 Audience Summary (2)

*Statistics taken from the 2nd Digital Biomarkers & Clinical Measures for Neurology Summit

What Your CNS Digital Health Peers Had to Say:

"Attending this conference offers a unique opportunity to deepen our understanding, expand professional networks, and contribute to the collective efforts aimed at improving the lives of individuals affected by neurological disorders."

Digital Healthcare Innovation, Business & Research Strategy, Mitsubishi Tanabe Pharma

“Good topics and speakers, also an intimate format where it was easy to network. I thought the 'speed dating' worked well.”

Senior Director, Lundbeck

“I am excited to dive deep into the ins and outs of applying digital biomarkers to tackle CNS disease with the leaders in the field. We have an opportunity to ensure digital biomarkers measure what matters to patients, and I hope that by bringing the experts together for a focused meeting we can accelerate progress. ”

Head, Real-World Research Networks, Biogen Digital Health (formerly)

“The size of the conference makes it incredibly easy to make connections. Additionally, the topics covered a wide range of issues related to digital biomarkers which was great.”

Principal Data Scientist, Takeda

“The nice mix of academics, pharma, and vendors in the space allowed for great dialogues, interesting presentations, and opportunities to network.”

Chief Medical Officer, Oryzon Genomics

“Great interactions and discussions, developed opportunities for collaboration and open discussions focused on the need to do better for patients.”

Neurologist, South Shore Hospital